WallStreetZenWallStreetZen

NASDAQ: FOLD
Amicus Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Amicus Therapeutics revenue was $634.21M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $185.2M, up 9.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, FOLD annual revenue was $634.2M, with 20% growth year-over-year.

FOLD past revenue growth

How has FOLD's revenue growth performed historically?

Company
20.05%
Industry
411.11%
Market
86.54%
FOLD's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
FOLD's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
FOLD's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

FOLD revenue history

Current Revenue
$634.2M
Current Earnings
-$27.1M
Current Profit Margin
-4.3%

Be the first to know when FOLD announces revenue.

FOLD Revenue History By Year

FOLD Yearly RevenueFOLD RevenueFOLD ChangeFOLD Revenue Growth
2025-12-31$634.21M$105.92M+20.05%
2024-12-31$528.30M$128.94M+32.29%
2023-12-31$399.36M$70.12M+21.30%
2022-12-31$329.23M$23.72M+7.76%
2021-12-31$305.51M$44.63M+17.11%
2020-12-31$260.89M$78.65M+43.16%
2019-12-31$182.24M$90.99M+99.72%
2018-12-31$91.25M$54.32M+147.08%
2017-12-31$36.93M$31.97M+644.86%
2016-12-31$4.96MN/AN/A
2015-12-31$0.00-$1.22M-100.00%
2014-12-31$1.22M$861.00k+237.19%
2013-12-31$363.00k-$18.05M-98.03%
2012-12-31$18.41M-$3.02M-14.10%
2011-12-31$21.43M$20.51M+2,224.73%
2010-12-31$922.00k-$63.44M-98.57%
2009-12-31$64.36M$49.39M+330.00%
2008-12-31$14.97M$13.18M+738.96%
2007-12-31$1.78MN/AN/A
2006-12-31$0.00N/AN/A
2005-12-31$0.00N/AN/A
2004-12-31$0.00N/AN/A

1 of 2

Amicus Therapeutics Revenue FAQ

What was FOLD's revenue last quarter?

On Invalid Date, Amicus Therapeutics (NASDAQ: FOLD) reported Q4 2025 revenue of $185.21 million up 23.72% year over year. In the same quarter last year, Amicus Therapeutics's revenue was $149.71 million.

What was Amicus Therapeutics's revenue in 2025?

Amicus Therapeutics's annual revenue for the twelve months ending Dec 31, 2025 was $634.21 million, a 20.05% increase year over year.

How much does Amicus Therapeutics make in a day?

Based on Amicus Therapeutics annual revenue for the past five years, FOLD makes an average of $1,203,620.82 per day.

What was Amicus Therapeutics's annual revenue growth in the past year?

As of Q1 2026, Amicus Therapeutics's revenue has grown 20.05% year over year. This is 391.06 percentage points lower than the US Biotechnology industry revenue growth rate of 411.11%. Amicus Therapeutics's revenue in the past year totaled $634.21 million.

How much does Amicus Therapeutics make in a year?

Amicus Therapeutics's revenue by year for the past five years is:
  • Amicus Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $634.21 million, a 20.05% increase year over year.
  • Amicus Therapeutics's annual revenue for Dec 31, 2024 was $528.30 million, a 32.29% increase from 2023.
  • Amicus Therapeutics's annual revenue for 2023 was $399.36 million, a 21.3% increase from 2022.
  • Amicus Therapeutics's annual revenue for 2022 was $329.23 million, a 7.76% increase from 2021.
  • Amicus Therapeutics's annual revenue for 2021 was $305.51 million, a 17.11% increase from 2020.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.